日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

首创转化生长因子-β 受体 I 型抑制剂 galunisertib（LY2157299 一水合物）的临床前评估

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.23795
Jonathan M Yingling, William T McMillen, Lei Yan, Huocong Huang, J Scott Sawyer, Jeremy Graff, David K Clawson, Karen S Britt, Bryan D Anderson, Douglas W Beight, Durisala Desaiah, Michael M Lahn, Karim A Benhadji, Maria J Lallena, Rikke B Holmgaard, Xiaohong Xu, Faming Zhang, Jason R Manro, Philip
信号转导
发表日期：2017
文献求助 收藏

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

一项 II 期随机研究，比较了加鲁尼塞替单药治疗或加鲁尼塞替联合洛莫司汀治疗与洛莫司汀单药治疗在复发性胶质母细胞瘤患者中的疗效。

期刊:Neuro-Oncology
影响因子:13.4
doi:10.1093/neuonc/now009
Brandes, Alba A; Carpentier, Antoine F; Kesari, Santosh; Sepulveda-Sanchez, Juan M; Wheeler, Helen R; Chinot, Olivier; Cher, Lawrence; Steinbach, Joachim P; Capper, David; Specenier, Pol; Rodon, Jordi; Cleverly, Ann; Smith, Claire; Gueorguieva, Ivelina; Miles, Colin; Guba, Susan C; Desaiah, Durisala; Lahn, Michael M; Wick, Wolfgang
细胞生物学
发表日期：2016
文献求助 收藏

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

三种不同制剂的加鲁尼塞替单药治疗晚期或转移性癌症患者的相对生物利用度

期刊:Drugs in Context
影响因子:2.8
doi:10.7573/dic.212303
Gueorguieva, Ivelina; Cleverly, Ann; Desaiah, Durisala; Azaro, Analia; Seoane, Joan; Braña, Irene; Sicart, Elisabet; Miles, Colin; Lahn, Michael M; Mitchell, Malcolm I; Rodon, Jordi
肿瘤
肿瘤免疫
发表日期：2016
文献求助 收藏

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer

PRONOUNCE：一项随机、开放标签的III期研究，比较一线培美曲塞+卡铂治疗后序贯培美曲塞维持治疗与紫杉醇+卡铂+贝伐单抗治疗后序贯贝伐单抗维持治疗在晚期非鳞状非小细胞肺癌患者中的疗效。

期刊:Journal of Thoracic Oncology
影响因子:20.8
doi:10.1097/JTO.0000000000000366
Zinner, Ralph G; Obasaju, Coleman K; Spigel, David R; Weaver, Robert W; Beck, J Thaddeus; Waterhouse, David M; Modiano, Manuel R; Hrinczenko, Borys; Nikolinakos, Petros G; Liu, Jingyi; Koustenis, Andrew G; Winfree, Katherine B; Melemed, Symantha A; Guba, Susan C; Ortuzar, Waldo I; Desaiah, Durisala; Treat, Joseph A; Govindan, Ramaswamy; Ross, Helen J
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.

galunisertib（LY2157299 一水合物）是一种转化生长因子-β信号通路的小分子抑制剂，目前正在进行临床开发

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S86621
Herbertz Stephan, Sawyer J Scott, Stauber Anja J, Gueorguieva Ivelina, Driscoll Kyla E, Estrem Shawn T, Cleverly Ann L, Desaiah Durisala, Guba Susan C, Benhadji Karim A, Slapak Christopher A, Lahn Michael M
信号转导
发表日期：2015
文献求助 收藏

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

在针对晚期癌症患者的 I 期研究中，对转化生长因子-β 受体 I 激酶抑制剂 galunisertib 进行药代动力学、药效学和生物标志物评估

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-014-0192-4
Rodón, Jordi; Carducci, Michael; Sepulveda-Sánchez, Juan M; Azaro, Analía; Calvo, Emiliano; Seoane, Joan; Braña, Irene; Sicart, Elisabet; Gueorguieva, Ivelina; Cleverly, Ann; Pillay, N Sokalingum; Desaiah, Durisala; Estrem, Shawn T; Paz-Ares, Luis; Holdhoff, Matthias; Blakeley, Jaishri; Lahn, Michael M; Baselga, Jose
信号转导
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

对阿托莫西汀滥用潜力评估的综述：一种用于治疗注意力缺陷/多动障碍的非兴奋剂药物

期刊:Psychopharmacology
影响因子:3.3
doi:10.1007/s00213-013-2986-z
Upadhyaya, Himanshu P; Desaiah, Durisala; Schuh, Kory J; Bymaster, Frank P; Kallman, Mary J; Clarke, David O; Durell, Todd M; Trzepacz, Paula T; Calligaro, David O; Nisenbaum, Eric S; Emmerson, Paul J; Schuh, Leslie M; Bickel, Warren K; Allen, Albert J
发表日期：2013
文献求助 收藏

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

度洛西汀60毫克每日一次治疗重度抑郁症的疗效和安全性：专家评论综述

期刊:Drugs in Context
影响因子:2.8
doi:10.7573/dic.212245
Ball, Susan G; Desaiah, Durisala; Zhang, Qi; Thase, Michael E; Perahia, David G S
抑郁症
神经科学
发表日期：2013
文献求助 收藏

Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries

药物治疗注意力缺陷多动障碍：非西方国家儿童和青少年的功能性结局

期刊:Drugs in Context
影响因子:2.8
doi:10.7573/dic.212260
Altin, Murat; El-Shafei, Ahmed A; Yu, Maria; Desaiah, Durisala; Treuer, Tamas; Zavadenko, Nikolay; Gao, Hong Yun
发表日期：2013
文献求助 收藏

Functional impairment related to painful physical symptoms in patients with generalized anxiety disorder with or without comorbid major depressive disorder: post hoc analysis of a cross-sectional study

伴或不伴有重度抑郁症的广泛性焦虑症患者疼痛性躯体症状相关的功能障碍：一项横断面研究的事后分析

期刊:BMC Psychiatry
影响因子:3.6
doi:10.1186/1471-244X-11-69
Romera, Irene; Montejo, Angel L; Caballero, Fernando; Caballero, Luis; Arbesú, José; Polavieja, Pepa; Desaiah, Durisala; Gilaberte, Inmaculada
抑郁症
焦虑症
神经科学
发表日期：2011
文献求助 收藏